Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial (Q34670965)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial |
scientific article |
Statements
1 reference
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial (English)
1 reference
Dirk Schadendorf
1 reference
Paolo A Ascierto
1 reference
Jedd D Wolchok
1 reference
Antoni Ribas
1 reference
F Stephen Hodi
1 reference
Tara C Gangadhar
1 reference
Ronnie Shapira-Frommer
1 reference
Jacob Schachter
1 reference
Christian U Blank
1 reference
Reinhard Dummer
1 reference
Igor Puzanov
1 reference
Omid Hamid
1 reference
Anna C Pavlick
1 reference
Karl D Lewis
1 reference
Lee D Cranmer
1 reference
Steven J O'Day
1 reference
April K S Salama
1 reference
Kim A Margolin
1 reference
Carmen Loquai
1 reference
Matteo S Carlino
1 reference
Sanjiv S Agarwala
1 reference
Stergios J Moschos
1 reference
Jeffrey A Sosman
1 reference
Simone M Goldinger
1 reference
Rene Gonzalez
1 reference
John M Kirkwood
1 reference
Xiaoyun Nicole Li
1 reference
Wei Zhou
1 reference
Adriane M Zernhelt
1 reference
Joy Lis
1 reference
Scot Ebbinghaus
1 reference
S Peter Kang
1 reference
1 reference
Identifiers
1 reference